Why the study?
Does apixaban improve cost-effectiveness compared to warfarin in Finnish patients with atrial fibrillation?
Does apixaban improve cost-effectiveness compared to warfarin in Finnish patients with atrial fibrillation?
Apixaban is a highly cost-effective alternative to warfarin for preventing thromboembolic complications in Finnish patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support apixaban use in Finnish AF; leaves open prospective validation.
The ICERs obtained were well below the WHO-CHOICE threshold values for cost-effective interventions, suggesting that apixaban is a very cost-effective treatment alternative for warfarin in Finnish patients with AF.
No takes yet. Share an insight, caveat, or question.
Hallinen et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: